279 related articles for article (PubMed ID: 32655498)
1. A Novel E2F1-EP300-VMP1 Pathway Mediates Gemcitabine-Induced Autophagy in Pancreatic Cancer Cells Carrying Oncogenic KRAS.
Ropolo A; Catrinacio C; Renna FJ; Boggio V; Orquera T; Gonzalez CD; Vaccaro MI
Front Endocrinol (Lausanne); 2020; 11():411. PubMed ID: 32655498
[TBL] [Abstract][Full Text] [Related]
2. Novel AKT1-GLI3-VMP1 pathway mediates KRAS oncogene-induced autophagy in cancer cells.
Lo Ré AE; Fernández-Barrena MG; Almada LL; Mills LD; Elsawa SF; Lund G; Ropolo A; Molejon MI; Vaccaro MI; Fernandez-Zapico ME
J Biol Chem; 2012 Jul; 287(30):25325-34. PubMed ID: 22535956
[TBL] [Abstract][Full Text] [Related]
3. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells.
Pardo R; Lo Ré A; Archange C; Ropolo A; Papademetrio DL; Gonzalez CD; Alvarez EM; Iovanna JL; Vaccaro MI
Pancreatology; 2010; 10(1):19-26. PubMed ID: 20299819
[TBL] [Abstract][Full Text] [Related]
5. The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation.
Loncle C; Molejon MI; Lac S; Tellechea JI; Lomberk G; Gramatica L; Fernandez Zapico MF; Dusetti N; Urrutia R; Iovanna JL
Cell Death Dis; 2016 Jul; 7(7):e2295. PubMed ID: 27415425
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
7. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
8. Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs.
Gilabert M; Vaccaro MI; Fernandez-Zapico ME; Calvo EL; Turrini O; Secq V; Garcia S; Moutardier V; Lomberk G; Dusetti N; Urrutia R; Iovanna JL
J Cell Physiol; 2013 Sep; 228(9):1834-43. PubMed ID: 23460482
[TBL] [Abstract][Full Text] [Related]
9. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
[TBL] [Abstract][Full Text] [Related]
11. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
[TBL] [Abstract][Full Text] [Related]
13. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
14. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
15. P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer.
Ono H; Basson MD; Ito H
Oncotarget; 2016 Aug; 7(32):51301-51310. PubMed ID: 27322077
[TBL] [Abstract][Full Text] [Related]
16. Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells.
Hong X; Li ZX; Hou J; Zhang HY; Zhang CY; Zhang J; Sun H; Pang LH; Wang T; Deng ZH
BMC Cancer; 2021 Jan; 21(1):33. PubMed ID: 33413231
[TBL] [Abstract][Full Text] [Related]
17. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
18. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
19. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
20. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
Kato H; Seto K; Kobayashi N; Yoshinaga K; Meyer T; Takei M
Life Sci; 2011 Oct; 89(17-18):603-8. PubMed ID: 21839751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
